| Identification | Back Directory | [Name]
Acetamide, 2-[2-(1,1-dimethylethyl)phenoxy]-N-(4-hydroxyphenyl)- | [CAS]
831243-31-3 | [Synonyms]
Acetamide, 2-[2-(1,1-dimethylethyl)phenoxy]-N-(4-hydroxyphenyl)- | [Molecular Formula]
C18H21NO3 | [MOL File]
831243-31-3.mol | [Molecular Weight]
299.36 |
| Chemical Properties | Back Directory | [Boiling point ]
529.2±45.0 °C(Predicted) | [density ]
1.169±0.06 g/cm3(Predicted) | [solubility ]
DMSO : ≥ 100 mg/mL (334.05 mM) | [form ]
Solid | [pka]
9.98±0.26(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
NAT is an initial hit of NAMPT activator. NAMPT is the rate-limiting enzyme in the NAD salvage pathway, which makes it an attractive target for the research of many diseases associated with NAD exhaustion such as neurodegenerative diseases[1]. | [in vivo]
NAT (30 mg/kg, ip, every day for 2 weeks) increases the mechanical hyperalgesia threshold, and exhibits neuroprotective effect in chemotherapy-induced peripheral neuropathy (CIPN) mouse model[1]. | Animal Model: | Chemotherapy-induced peripheral neuropathy (CIPN) mouse model[1] | | Dosage: | 30 mg/kg | | Administration: | ip, every day for 2 weeks | | Result: | Increased the mechanical pain threshold of mice, increased the level of NAD? in the sciatic nerves. |
| [References]
[1] Wang L, et al. Optimization of NAMPT activators to achieve in vivo neuroprotective efficacy [published online ahead of print, 2022 Mar 16]. Eur J Med Chem. 2022;236:114260. DOI:10.1016/j.ejmech.2022.114260 |
|
|